TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: early diagnosis of invasive fungal infection (IFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Subjects Who Demonstrate Sustained Unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of toilet training
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: N Antibody, Geometric Mean Titer (GMT) to Dengue Serotypes 1, 2, 3 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Seropositive for Dengue Serotypes 1, 2, 3 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 of Study Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in practitioner's stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3T Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ln(Bacterial Colony Count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Bacterial Species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recommended dose determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessment of trial regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Treg response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of HKI-272 formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to report symptoms from concussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Drug-related Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Relevant Abnormalities in Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average end expiratory alveolar concentration of Carbon monoxide (ppm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Hepatitis B Surface (HBs) Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained virological response (SVR) at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to oral anticancer treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anti-CS antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with a favorable response to Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate decrease in mean pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary patency of the stent or graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of pain assessed with the Visual Analogic Scale Questionnaire (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Postraumatic Stress Disorder (PTSD) evaluated with the Evaluación Global de Estrés Postraumático (EGEP-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of depressive symptoms assessed by the Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte frataxin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to healing of the primary lesion complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alterations in total Volatile Organic Compounds (tVOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alterations in particulate matter (PM2.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 6 (IL-6) Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HAQ Score Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence/absence of cortico-sparing treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of family members informed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Parasympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulation of parasympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Presenting With Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Rate of Stages/Grade of ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in weight (child)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical changes in liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of asthenia in patients
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Evaluation of liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in hepatic encephalopathy indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Erythrocyte Volume Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Total Creatine Phosphokinase (CPK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVmax of stenotic intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MV of stenotic intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMI of stenotic intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature Ejaculation Diagnostic Tool (Total Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development and progress of Cerebellar Mutism Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate Vigorous Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression - Improvement (CGI-I) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemodynamic Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of patients achieving ACR 20, 50, 70 and 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tridimensional tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrity of the corticospinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor function of muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HLA matching rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause dementia
Endpoint domain: Mortality/survival
Primary endpoint: Maximum rate of change in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants diagnosed with sexual dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Serotype Ia GBS IgG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Serotype III GBS IgG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Serotype Ib GBS IgG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Weekly Mean of the 24-hour Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gesell scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Photographic Images of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Traveled by Breast Clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Equilibrium Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss after bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Co-morbidities rate following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with an anti-influenza titer >= 1:40 HI units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission From Major Depressive Episode
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulated postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of meals containing vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Mosapirde citrate 5mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Mosapirde citrate 5mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Rebamipide 100mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Rebamipide 100mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare Cost
Endpoint domain: Resource use
Primary endpoint: PedsQL 4.0 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of dnDSA
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of AMR
Endpoint domain: Adverse events/effects
Primary endpoint: corrected minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MCP-1 On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cyp-A On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actin-NT On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-NT On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-17 On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nfl On-treatment Period Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemagglutination Inhibition (HI) Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Utilization of breast and ovarian cancer risk management options
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Female Sexual Function Index scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total dose of exposure to 5-FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sPLA2 Levels in EBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Plasma and Blood Cell Vitamin and Mineral Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Half life (T 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-years disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in the belief in misinformation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on the Clinical Outcomes in Routine Evaluation (CORE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting throat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing throat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative wound infection or wound bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of hs-CRP, hemoglobin, neutrophil%, and WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in MDS-UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of rescue analgesia in the first 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With HBV DNA <20 IU Per mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength (1RM, Isometric)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stair test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma troponin I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality during follow up
Endpoint domain: Mortality/survival
Primary endpoint: serum S-100β level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III-IV Toxicities or Any Grade II Toxicities Lasting More Than 2 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of contrast induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients who complete the entire cycle
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tolerability of Orenitram
Endpoint domain: Adverse events/effects
Primary endpoint: Global Assessment of Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: platelet expression of glycoprotein IIb/IIIa receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-application fatigue severity rate
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Decrease in sleep quality scale scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of Participants With No Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contacts with the care provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC (0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with dilated iris ≥ 6 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-rated ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teacher-rated ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Influenza Like Illness (ILI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SLICC-ACR Damage Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Sciatica pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic Assessment of change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUCg from 2-hour OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Late Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance of subsequent visits for routine immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta2-microglobulin removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion of the aneurysm sac or target vessel at immediate post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion of the aneurysm sac or target vessel at one year post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural device-related serious adverse events at immediate post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Sedation success with EEG study completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery from sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of single support at each leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorical Reactivity to Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Grade 2 or more toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients on monotherapy vs combination therapies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cerebrovascular autoregulation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increasing clinic attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ankle-Brachial Index Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of patients achieving and maintaining targeted esophageal pressure swings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the QMG Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Depression Questionnaire (PDQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients Meeting Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Occupational Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Corneal perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in Neuropsychological Battery scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Higher Risk Patients Evaluated Thoroughly for Abuse
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Lower Risk Patients Evaluated Even Partially for Abuse
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Estimated Rates of Missed AHT
Endpoint domain: Adverse events/effects
Primary endpoint: physical activity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stans Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of serum sclerostin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of serum Dickkopf1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Diagnosed Non-cholerae or Non-O1/O139 Vibrio Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Time in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of somatic comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transfusion incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Fridericia's corrected QT (ΔQTcF) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease-specific health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor recurrence rate in one or two years
Endpoint domain: Mortality/survival
Primary endpoint: Gut inflammation assessed by stool Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Severity of Hardware Related Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Enteral Feeding (FEF) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes